The PathFlow® SARS-CoV-2 IgG is an easy-to-use, rapid, lateral flow test, for the detection of antibodies in human whole blood, serum, or plasma specimen(s).

**Specifications**
- Sensitivity – 98%
- Specificity – 99%
- Rapid results – 10-20 minutes
- Sample types – Whole Blood/Serum/Plasma
- Kit size – 25 tests
- Ambient storage – 2-30°C
- Product code – M598CE

.Tested on over 240 positive and 219 negative samples

**Why antibody testing?**
Antibody testing was initially used for the sole purpose of sero-surveillance and infection monitoring. However, its deployment is changing alongside increasing prevalence – especially in conjunction with immunisation campaigns and operations.

Understanding if a person has developed an immune response to SARS-CoV-2 as a result of either infection or vaccination, is a pivotal step in our combat against the virus.

**What is the test?**
The assay provides detection of IgG antibodies to SARS-CoV-2 spike (S) protein, receptor binding domain (RBD) and nucleocapsid (N) protein.

The test is to aid in the identification of individuals with an adaptive immune response to SARS-CoV-2; derived from wild type infection or as a response to vaccination.

www.microgenbioproducts.com

**Product utilisation**
- Sero-surveillance
- Vaccine efficacy
- Academia and research
- Immunity passports
- Private testing laboratories
What are neutralising antibodies (NAb)?

NAb are an indication of protective immunity for most viral infections. Their presence is provoked by either natural infection or immunisation.

Not only do they bind to a virus, but their interactions also inhibit infection. This binding is incredibly specific to epitopes found on the virus surface.

For the case of SARS-CoV-2, these antigenic determinants are predominantly located in the ‘S’ protein, principally ‘RBD’.

Why use PathFlow®

The PathFlow® SARS-CoV-2 IgG rapid test delivers a high performing and reliable method for the detection of antibodies to the ‘S’ (RBD) and ‘N’ proteins of SARS-CoV-2.

PathFlow® offers an easy-to-use solution for antibody testing, without the need for complex levels of equipment or technical knowledge.

The assay also provides a rapid turnaround time, with results available from 10-20 minutes.

Not only could PathFlow® be used to monitor previous infection prevalence, it may also act as a critical tool to assess vaccine efficacy and subsequent protection offered.

The PathFlow® lateral flow testing portfolio entails a broad range of infectious disease diagnostic solutions.